PTMA gene raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-14. Anything still debated is marked as such rather than presented as settled.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Epigenetics is the study of heritable changes in gene function that cannot be explained by changes in the underlying DNA sequence but cause the organism's genes to behave (or "express themselves") differently. One example of epigenetic change is the marking of the genes by DNA methylation which determines whether they will be expressed or not. Gene expression can also be controlled by repressor proteins that attach to silencer regions of the DNA and prevent that region of the DNA code from being expressed. Epigenetic marks may be added or removed from the DNA during programmed stages of development of the plant, and are responsible, for example, for the differences between anthers, petals and normal leaves, despite the fact that they all have the same underlying genetic code. Epigenetic changes may be temporary or may remain through successive cell divisions for the remainder of the cell's life. Some epigenetic changes have been shown to be heritable, while others are reset in the germ cells. Epigenetic changes in eukaryotic biology serve to regulate the process of cellular differentiation. During morphogenesis, totipotent stem cells become the various pluripotent cell lines of the embryo, which in turn become fully differentiated cells. A single fertilised egg cell, the zygote, gives rise to the many different plant cell types including parenchyma, xylem vessel elements, phloem sieve tubes, guard cells of the epidermis, etc. as it continues to divide. The process results from the epigenetic activation of some genes and inhibition of others.
Medical acupuncture attempts to integrate reflexological concepts, the trigger point model, and anatomical insights (such as dermatome distribution) into acupuncture practice, and emphasizes a more formulaic approach to acupuncture point location. Cosmetic acupuncture is the use of acupuncture in an attempt to reduce wrinkles on the face. Bee venom acupuncture is a treatment approach of injecting purified, diluted bee venom into acupoints. Veterinary acupuncture is the use of acupuncture on domesticated animals.
== Further reading == Centers for Disease Control and Prevention (2012). "Ch. 7: Haemophilus influenzae". In Atkinson W; Wolfe S; Hamborsky J (eds.). Epidemiology and Prevention of Vaccine-Preventable Diseases (12th ed.). Washington, D.C.: Public Health Foundation. pp. 87–100. Archived from the original on 2017-03-10. "Haemophilus influenzae". NCBI Taxonomy Browser. 727.
=== Systematic reviews identifying safety signals === A 2013 comprehensive systematic review by Dr. Salvatore Gentile concluded that second‑generation long‑acting injectable antipsychotics (SGA‑LAIs) "seem to also show unforeseen and worrisome safety signals," and noted that "worsening of psychotic symptoms and depression could also be associated with both risperidone‑LAI and paliperidone palmitate." The leading cause of death among patients enrolled in risperidone‑LAI studies was suicide. A 2017 systematic update by the same author concluded that SGA‑LAIs "do not offer advantages in safety compared with first‑generation antipsychotic LAIs or oral antipsychotics," and highlighted weight gain, hyperprolactinemia, and the finding that the three‑monthly paliperidone palmitate formulation still lacked exhaustive safety data.
Sources: en.wikipedia.org
== Awards == Silver medal, 2022 International KIWIE Award Silver medal, 2023 International KIWIE Award. Women Inventor Award, INDECOPI. Top 10 iCAN Award, from Canada for her ongoing projects. Hipolito Unanue Institute Fountation Award, Best Scientific Research Work for the study "Frequency of CYP1A1*2A and deletion of the GSTM1 gene in the Peruvian mestizo population". Three gold medals, 2024 International KIWIE Awards
== Membership of professional bodies == Member of the Governing Council of the Pharmacists Council of Nigeria, Nnamdi Azikiwe University Member of the Nanomedicine Society of Nigeria Member of the Global Young Academy Member of the American Society for Cell biology Member of many other professional bodies including, Institute of Public Analysts of Nigeria; West African Society for Pharmacology, Nigeria; Society for Medicinal Plant Research, Germany; Pan African Medical Mycology Society, South Africa; International Society for Anti-infective Pharmacology; Materials Society of Nigeria; and, Nigerian Society of Forensic Scientists (Pioneer member of Board of Directors)
In November 1997 National Theatre of Greece launched a worldwide tour of Medea, a critically acclaimed production directed by Nikaiti Kontouri, starring Karyofyllia Karambeti as Medea, Kostas Triantafyllopoulos as Creon and Lazaros Georgakopoulos as Jason. The tour included performances in France, Australia, Israel, Portugal, United States, Canada, Turkey, Bulgaria, China and Japan and lasted almost two years, until July 1999. The play opened in the United States at Shubert Theatre in Boston (18 and 19 September 1998) and then continued at City Center Theatre in Manhattan, New York City (23 to 27 September 1998), receiving a very positive review from The New York Times. Neil LaBute wrote Medea Redux, a modern retelling, first performed in 1999 starring Calista Flockhart, as part of his one-act trilogy entitled Bash: Latter-Day Plays. In this version, the main character is seduced by her middle-school teacher. He abandons her, and she kills their child out of revenge. Michael John LaChiusa created a Broadway musical adaptation work for Audra McDonald entitled Marie Christine in 1999. McDonald portrayed the title role, and the show was set in 1890s New Orleans and Chicago. Liz Lochhead's Medea previewed at the Old Fruitmarket, Glasgow as part of Theatre Babel's Greeks in 2000 before the Edinburgh Fringe and national tour. "What Lochhead does is to recast MEDEA as an episode-ancient but new, cosmic yet agonisingly familiar- in a sex war which is recognisable to every woman, and most of the men, in the theatre", wrote The Scotsman.
These include radionuclides occurring in the decay chains of primordial uranium and thorium (radiogenic nuclides), such as radon-222. Others are the products of interactions with energetic cosmic rays (the cosmogenic nuclides), such as carbon-14. This gives a total of about 350 naturally occurring nuclides, some of which are difficult to detect. Other nuclides may be occasionally produced naturally by rare cosmogenic interactions or as a result of other natural nuclear reactions (nucleogenic nuclides), and these are generally even less detectable. Non-primordial nuclides may also be detected in the spectra of stars; technetium is well established, and others have been claimed. The remaining nuclides are known solely from artificial nuclear transmutations. Some, such as caesium-137 and krypton-85, are detected in the environment, but only (or practically only) from deliberate or accidental release of artificial production, as fission products (from nuclear weapons or nuclear reactors), for industrial or medical uses, or otherwise.
Leonian Gyoku Rou (レオン星人ギョク・ロウ, Reon Seijin Gyoku Rō): Ban's leonine predecessor, from Planet Leon, who was meant to become Deka Red on Earth, but was badly injured while protecting Jasmine and Hoji from an Alienizer called Terry X, which seemingly forced Rou to retire. In reality, he was tasked by Numa-O to go underground and prepare an elite team called the Fire Squad (ファイヤースクワッド, Faiyā Sukuwaddo). In the present, after being forced out of hiding when Terry X resurfaces, Rou recruits Ban in recognition of his fiery passion and drive for crime-fighting. Gyoku Rou is voiced by Daisuke Namikawa (浪川 大輔, Namikawa Daisuke).
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.